BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1518268)

  • 21. Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages.
    Bökkerink JP; De Abreu RA; Bakker MA; Hulscher TW; van Baal JM; Schretlen ED; De Bruijn CH
    Biochem Pharmacol; 1988 Jun; 37(12):2329-38. PubMed ID: 2455520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia.
    Bostrom B; Erdmann G
    Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):80-6. PubMed ID: 8447563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed cytotoxicity of 6-mercaptopurine is compatible with mitotic death caused by DNA damage due to incorporation of 6-thioguanine into DNA as 6-thioguanine nucleotide.
    Inamochi H; Higashigawa M; Shimono Y; Nagata T; Cao DC; Mao XY; M'soka T; Hori H; Kawasaki H; Sakurai M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):417-24. PubMed ID: 10606189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
    Tolar J; Bostrom BC; La MK; Sather HN
    Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo.
    Tosi P; Calabresi P; Goulette FA; Renaud CA; Darnowski JW
    Cancer Res; 1992 Aug; 52(15):4069-73. PubMed ID: 1638518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the effects of several inhibitors of the synthesis of nucleic acids upon the viability and progression through the cell cycle of cultured H. Ep. no. 2 cells.
    Wheeler GP; Bowdon BJ; Adamson DJ; Vail MH
    Cancer Res; 1972 Dec; 32(12):2661-9. PubMed ID: 4264728
    [No Abstract]   [Full Text] [Related]  

  • 30. Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
    Zhen YS; Taniki T; Weber G
    Oncol Res; 1992; 4(2):73-8. PubMed ID: 1596584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
    Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythrocyte concentrations of metabolites or cumulative doses of 6-mercaptopurine and methotrexate do not predict liver changes in children treated for acute lymphoblastic leukemia.
    Halonen P; Mattila J; Mäkipernaa A; Ruuska T; Schmiegelow K
    Pediatr Blood Cancer; 2006 Jun; 46(7):762-6. PubMed ID: 16395677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.
    Capizzi RL
    Cancer Treat Rep; 1981; 65 Suppl 4():115-21. PubMed ID: 7049375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture.
    Kano Y; Ohnuma T; Okano T; Holland JF
    Cancer Res; 1988 Jan; 48(2):351-6. PubMed ID: 3422052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow.
    Koizumi S; Curt GA; Fine RL; Griffin JD; Chabner BA
    J Clin Invest; 1985 Mar; 75(3):1008-14. PubMed ID: 2579975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methotrexate cytotoxicity in cultured human leukemic cells studied by flow cytometry.
    Taylor IW; Tattersall MH
    Cancer Res; 1981 Apr; 41(4):1549-58. PubMed ID: 6163527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
    Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
    Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia.
    Lönnerholm G; Valsecchi MG; De Lorenzo P; Schrappe M; Hovi L; Campbell M; Mann G; Janka-Schaub G; Li CK; Stary J; Hann I; Pieters R;
    Pediatr Blood Cancer; 2009 May; 52(5):596-601. PubMed ID: 19132729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Some biochemical characteristics of L1210 cell lines resistant to 6-mercaptopurine and 6-thioguanine and with increased sensitivity to methotrexate.
    Strobel-Stevens JD; El Dareer SM; Trader MW; Hill DL
    Biochem Pharmacol; 1982 Oct; 31(19):3133-7. PubMed ID: 6890814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
    Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O
    J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.